Track market-moving stories before they get noisy

Key Takeaways Invesco's Q2 results are expected to reflect y/y earnings and revenue growth.IVZ's preliminary AUM reached $2.47T in June 2026, supporting investment management fees.IVZ completed its Canadian fund business transfer to CI GAM while retaining select portfolio mandates. Invesco (IVZ - Free Report) is scheduled to announce second-quarter 2026 results on July 28, before market open. The company’s quarterly earnings and revenues are expected to have witnessed a rise on a year-over-year basis.

In the last reported quarter, IVZ’s adjusted earnings missed the Zacks Consensus Estimate. The results primarily benefited from an increase in adjusted revenues and growth in assets under management (AUM) balance. However, an increase in adjusted expenses was a headwind.

Invesco does not have an impressive earnings surprise history. Its earnings surpassed the Zacks Consensus Estimate in only two of the trailing four quarters, the average surprise being 7.9%.

Invesco’s Key Q2 Estimates & Factors to NotePer the monthly metrics data published by Invesco, its preliminary total AUM as of June 30, 2026, was $2.47 trillion, up 14.4% from the previous quarter’s end. So, the company’s investment management fees are expected to have been positively impacted in the quarter. The Zacks Consensus Estimate for investment management fees is pegged at $1.48 billion, indicating a rise of 6.8% from the previous quarter.

The consensus estimate for service and distribution fees of $323 million indicates a rise of 7% from the previous quarter’s reported number. Also, the Zacks Consensus Estimate for other revenues is pegged at $63 million, suggesting a 28% sequential increase.

However, the company’s performance fee is expected to have declined sequentially because the previous quarter benefited from relatively stronger realizations in performance-fee-eligible strategies, particularly in private markets, fundamental fixed income and multi-asset products. In the to-be-reported quarter, performance fees are likely to have normalized to a lower level, reflecting the inherently lumpy nature of these revenues and the absence of any indication of unusually large performance-fee realizations during the quarter. The Zacks Consensus Estimate for second-quarter performance fees of $6.02 million indicates a 46.7% decline from the previous quarter’s actual.

On the cost front, while Invesco’s cost-saving initiatives are likely to have boosted its efficiency, the rise in compensation and marketing costs is expected to have had an adverse impact on overall expenses in the to-be-reported quarter.

Management expects one-time implementation costs of Alpha to be $10-$15 million in the second quarter of 2026.

Major Q2 Development for InvescoIn June, Invesco completed the transfer of its Canadian fund management business to CI Global Asset Management (CI GAM), marking the close of a deal that significantly reshapes the Canadian investment fund landscape.

The transaction, announced in January, involved management agreements tied to Invesco’s Canadian fund lineup, which oversees approximately C$27 billion in assets. Now, CI GAM has assumed management responsibilities for 98 mutual funds and ETFs that were previously operated by Invesco Canada.

Although management of the funds has shifted to CI GAM, Invesco will continue to play an important role through a long-term strategic partnership between the two firms. Under a sub-advisory arrangement, Invesco affiliates will keep providing portfolio management services for 61 funds representing roughly C$13 billion in assets.

What Our Model Predicts for IVZAccording to our proven model, the chances of Invesco beating the Zacks Consensus Estimate for earnings this time are high. This is because it has the right combination of the two key ingredients — a positive Earnings ESP and a Zacks Rank #3 (Hold) or better.

You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.

Earnings ESP: The Earnings ESP for Invesco is +0.08%.

Zacks Rank: The company currently carries a Zacks Rank #2 (Buy).

Invesco’s Q2 Earnings & Sales EstimatesThe Zacks Consensus Estimate for Invesco’s earnings of 67 cents per share has been unchanged over the past seven days. However, the figure indicates a rise of 86.1% from the year-ago quarter’s actual.

The consensus estimate for sales is pegged at $1.33 billion, suggesting a year-over-year increase of 20.1%.

Other Finance Stocks Worth ConsideringHere are a couple of other finance stocks that you may want to consider, as our model shows that these, too, have the right combination of elements to post an earnings beat this time:

Prosperity Bancshares (PB - Free Report) is scheduled to report quarterly results on July 29. The company currently has an Earnings ESP of +1.76% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Over the past seven days, the Zacks Consensus Estimate for PB’s quarterly earnings has been unchanged at $1.54.

The Earnings ESP for Affiliated Managers Group (AMG - Free Report) is +1.86% and it carries a Zacks Rank #2 at present. The company is slated to report quarterly results on July 30.

Over the past seven days, the Zacks Consensus Estimate for AMG’s quarterly earnings has been unchanged at $7.85.

Vanguard Health Care ETF (VHT -0.70%) and Invesco Pharmaceuticals ETF (PJP -0.84%) differ primarily in scope and cost, as the Vanguard fund provides broad sector coverage for a fraction of the Invesco fund price.

Healthcare investors often choose between broad sector exposure and thematic niches. The Vanguard fund provides a wide net across the entire industry, whereas the Invesco fund targets the research and manufacturing segments of the U.S. drug market exclusively. The choice -- broad versus narrow -- impacts everything from volatility to income potential.

Snapshot (cost & size)MetricPJPVHTIssuerInvescoVanguardShare price$117.91 (as of 2026-07-20)$299.49 (as of 2026-07-20)Expense ratio0.57%0.09%1-yr return (as of July 20, 2026)45.10%25.20%Dividend yield0.90%1.60%Beta0.450.60AUM$435.5 million$20.4 billionBeta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.VHT is significantly more affordable, sporting an expense ratio of 0.09% compared to 0.57% for PJP. The Vanguard fund also offers a higher payout, with a yield gap of 0.68 percentage points over its peer.

Performance & risk comparisonMetricPJPVHTMax drawdown (5 yr)(17.50%)(17.70%)Growth of $1,000 over 5 years (total return)$1,540$1,281What's insideThe Vanguard fund tracks a wide range of medical firms, holding 411 stocks, nearly all of which are in the healthcare sector. The fund’s largest positions include Eli Lilly & Co (LLY -0.97%) at 14.2%, Johnson & Johnson (JNJ +2.00%) at 8.9%, and AbbVie Inc (ABBV -0.90%) at 6.5%. It was launched in 2004. Vanguard Health Care ETF has paid $4.72 per share over the trailing 12 months, which on its recent ~$299.49 share price works out to a 1.60% yield.

In contrast, the Invesco fund focuses narrowly on just 29 stocks within the pharmaceutical space. Its top holdings include AbbVie at 5.6%, Eli Lilly at 5.4%, and Johnson & Johnson at 5.2%. The fund was launched in 2005. Invesco Pharmaceuticals ETF has paid $1.06 per share over the trailing 12 months, which on its recent ~$117.91 share price works out to a 0.90% yield.

Which fund is the better buy?Healthcare has been on a good run the past year, as a sector it is up around 25% the past 52 weeks. Both these funds are good ways to add this sector-specific exposure to your portfolio, but they have distinct differences investors should take into account to decide which one to buy.

While the Vanguard fund, VHT, holds many more securities, the less diverse Invesco fund, PJP, has much more of its portfolio in small cap stocks, 43% of its holdings, compared to 12% for VHT.  The Vanguard fund has 67% of its holdings in large-cap stocks, mostly value stocks, versus 43% for PJP. Both funds have roughly half their assets in their top 10 holdings.

The concentrated approach of Invesco’s PJP appears to be working well. The fund has returned 17.3%, 9.1%, and 7.5% over the 3-year, 5-year, and 10-year time frames.

VHT beats PJP in the 1-year look-back with 10.3% annualized returns, but it trails PJP notably in the 3- and 5-year time frames, with returns of 8.6% and 5.4%, respectively.

So which fund is the better buy? The Vanguard fund’s rock-bottom expense ratio is a strong trait in its favor, but it is hard to ignore the consistent outperformance of PJP over the past five years and year-to-date. The better buy for 2026 for healthcare exposure is PJP.

For more guidance on ETF investing, check out the full guide at this link.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.

Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.

How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.

That's where the Style Scores come in.

You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.

Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.

For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Invesco (IVZ - Free Report) Headquartered in Atlanta, GA, Invesco Ltd. operates as an independent investment manager and offers a wide range of investment products and services. The company was incorporated in 1935. As of March 31, 2026, Invesco served clients in more than 120 countries and had AUM worth $2.16 trillion.

IVZ is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.

Additionally, the company could be a top pick for growth investors. IVZ has a Growth Style Score of B, forecasting year-over-year earnings growth of 37% for the current fiscal year.

For fiscal 2026, six analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.20 to $2.78 per share. IVZ boasts an average earnings surprise of +7.9%.

With a solid Zacks Rank and top-tier Growth and VGM Style Scores, IVZ should be on investors' short list.

, /PRNewswire/ -- Invesco Mortgage Capital Inc. (NYSE: IVR) will announce its second quarter 2026 results Thursday, July 30, 2026, after market close. A conference call and audio webcast to review second quarter 2026 results will be held on Friday, July 31, 2026, at 9:00 a.m. ET. Scheduled to speak are Kevin Collins, Chief Executive Officer; David Lyle, President; Brian Norris, Chief Investment Officer; and Mark Gregson, Chief Financial Officer.

A presentation will be available on the Company's Web site at www.invescomortgagecapital.com prior to the call.

Those wishing to participate should call:

North America Toll Free:  888-982-7409
International Toll:             1-212-287-1625
Passcode:                        Invesco
Please visit the following site to join the call: Event Calendar - Invesco Mortgage Capital Inc.

An audio replay will be available until August 14, 2026, by calling:

866-363-1806 (North America) or 1-203-369-0194 (International).

About Invesco Mortgage Capital Inc.
Invesco Mortgage Capital Inc. is a real estate investment trust that primarily focuses on investing in, financing and managing agency mortgage-backed securities. Invesco Mortgage Capital Inc. is externally managed and advised by Invesco Advisers, Inc., a registered investment adviser and an indirect, wholly-owned subsidiary of Invesco Ltd., a leading independent global investment management firm. Additional information is available at www.invescomortgagecapital.com.

Investor Relations Contact: Greg Seals, 404-439-3323

SOURCE Invesco Mortgage Capital Inc.

All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.

While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its dividend yield, a metric that measures a dividend as a percent of the current stock price. Many academic studies show that dividends make up large portions of long-term returns, and in many cases, dividend contributions surpass one-third of total returns.

Invesco (IVZ - Free Report) is headquartered in Atlanta, and is in the Finance sector. The stock has seen a price change of 12.79% since the start of the year. The investment management company is paying out a dividend of $0.22 per share at the moment, with a dividend yield of 2.9% compared to the Financial - Investment Management industry's yield of 2.76% and the S&P 500's yield of 1.33%.

Looking at dividend growth, the company's current annualized dividend of $0.86 is up 3% from last year. Over the last 5 years, Invesco has increased its dividend 5 times on a year-over-year basis for an average annual increase of 7.66%. Looking ahead, future dividend growth will be dependent on earnings growth and payout ratio, which is the proportion of a company's annual earnings per share that it pays out as a dividend. Invesco's current payout ratio is 39%, meaning it paid out 39% of its trailing 12-month EPS as dividend.

Earnings growth looks solid for IVZ for this fiscal year. The Zacks Consensus Estimate for 2026 is $2.78 per share, representing a year-over-year earnings growth rate of 36.95%.

Investors like dividends for a variety of different reasons, from tax advantages and decreasing overall portfolio risk to considerably improving stock investing profits. However, not all companies offer a quarterly payout.

For instance, it's a rare occurrence when a tech start-up or big growth business offers its shareholders a dividend. It's more common to see larger companies with more established profits give out dividends. Income investors have to be mindful of the fact that high-yielding stocks tend to struggle during periods of rising interest rates. That said, they can take comfort from the fact that IVZ is not only an attractive dividend play, but also represents a compelling investment opportunity with a Zacks Rank of #2 (Buy).

474 Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Readers are advised to fact-check thoroughly before committing any capital to this idea; this reflects the personal views of the author and should not be pursued as formal financial or investment advice in any manner. While every effort has been made to ensure accuracy, errors may exist in the data and financial projections presented. The author is not responsible for any financial gains or losses incurred from investments made based on this content.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Invesco Aerospace & Defense ETF offers a slightly lower expense ratio and holds significantly larger assets under management (AUM) than U.S. Global Jets ETF U.S. Global Jets ETF provides a higher trailing-12-month dividend yield but has experienced much deeper drawdowns over the last five years The two funds offer distinct industrial focuses, with Invesco Aerospace & Defense ETF targeting defense and space while U.S. Global Jets ETF tracks commercial airline operators

Invesco S&P 500 Equal Weight Health Care ETF (RSPH 1.70%) offers equal-weighted exposure to the broad healthcare sector, whereas VanEck Biotech ETF (BBH 0.81%) concentrates heavily on the 25 largest biotechnology companies.

Investors may choose among these funds based on their preference for industry-specific concentration or diversified exposure to healthcare. While RSPH targets a wider range of medical services and products with a balanced weighting, BBH focuses strictly on the biotechnology industry using a market-cap-weighted model.

Snapshot (cost & size)MetricBBHRSPHIssuerVanEckInvescoShare price$205.55 (as of 2026-07-10)$33.98 (as of 2026-07-10)Expense ratio0.35%0.40%1-yr return (as of 2026-07-10)28.20%16.40%Dividend yield0.50%0.70%Beta0.680.78AUM$400.0 million$734.1 millionBeta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield as of the July 10 close.

The VanEck fund is the more affordable option with an expense ratio of 0.35%, compared to 0.40% for the Invesco fund. In terms of income, RSPH provides a marginally higher trailing dividend yield of 0.70% versus 0.50% for BBH.

Performance & risk comparisonMetricBBHRSPHMax drawdown (5 yr)(39.90%)(22.00%)Growth of $1,000 over 5 years (total return)$1,052$1,177What's insideThe Invesco S&P 500 Equal Weight healthcare ETF provides exposure to the broad healthcare sector by equally weighting constituents of the S&P 500 Index. This approach ensures that smaller constituents have as much influence on performance as industry giants. Its largest positions include Moderna (MRNA +0.57%) at 2.5%, Bio-Techne (TECH 0.18%) at 2.2%, and Charles River Laboratories International (CRL +0.64%) at 2%. It holds 60 securities and was launched in 2006. Invesco S&P 500 Equal Weight Health Care ETF has paid $0.23 per share over the trailing 12 months, which on its recent ~$33.98 share price works out to a 0.70% yield.

The VanEck Biotech ETF focuses exclusively on 25 of the largest and most liquid U.S.-listed biotechnology companies. Its portfolio is market-cap-weighted, which leads to a heavy concentration in a handful of industry leaders. Its largest positions include Amgen (AMGN 1.42%) at 15.1%, Gilead Sciences (GILD 1.03%) at 12.8%, and Vertex Pharmaceuticals (VRTX 0.82%) at 9.1%. The fund was launched in 2011. VanEck Biotech ETF has paid $0.96 per share over the trailing 12 months, which on its recent ~$205.55 share price works out to a 0.50% yield.

Which fund is the better buy?Both of these ETFs focus on the booming healthcare and biopharma industries, each dedicated solely to U.S.-listed equities. Interestingly, both are 54% in mid-cap stocks, with their differences coming from their large-cap and small-cap weightings.

BBH, the VanEck fund, is 8% in small caps, which aligns with its parameters to invest in the top 25 most liquid biotech stocks, which tend to be more large-cap. BBH has 38% of its holdings in large caps, mostly value-style companies.

The Invesco fund, RSPH, is more into small caps, at 19% of holdings, with 28% in large caps. It’s less concentrated in its top names, with 19% of its assets dedicated to its top 10 holdings compared to a highly concentrated 70% in the top 10 for BBH.

Performance-wise, the focus on a few popular names has worked very nicely for BBH. It has bested RSPH in every time frame but the 5-year and 10-year periods. BBH has tallied returns of 9.8%, 0.6%, and 7.8% over the 3-year, 5-year, and 10-year look-backs. By comparison, RSPH has returned 4.4%, 3.3%, and 8.9% over the 3-, 5-, and 10-year periods.

There is risk in going after BBH’s performance, as witnessed by its much higher maximum drawdown than RSPH. Yet the VanEck fund’s near- and mid-term performance has been consistently strong, making BBH the ETF to buy for biotech exposure in 2026.

For more guidance on ETF investing, check out the full guide at this link.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels.

On top of the Zacks Rank, investors can also look at our innovative Style Scores system to find stocks with specific traits. For example, value investors will want to focus on the "Value" category. Stocks with high Zacks Ranks and "A" grades for Value will be some of the highest-quality value stocks on the market today.

Invesco (IVZ - Free Report) is a stock many investors are watching right now. IVZ is currently sporting a Zacks Rank #2 (Buy), as well as an A grade for Value. The stock is trading with P/E ratio of 10.45 right now. For comparison, its industry sports an average P/E of 13.54. Over the past year, IVZ's Forward P/E has been as high as 11.12 and as low as 6.39, with a median of 9.43.

Value investors also frequently use the P/S ratio. This metric is found by dividing a stock's price with the company's revenue. This is a popular metric because sales are harder to manipulate on an income statement, so they are often considered a better performance indicator. IVZ has a P/S ratio of 1.91. This compares to its industry's average P/S of 3.15.

Value investors will likely look at more than just these metrics, but the above data helps show that Invesco is likely undervalued currently. And when considering the strength of its earnings outlook, IVZ sticks out as one of the market's strongest value stocks.

Jeffrey H. Kupor, a senior managing director of Invesco Ltd. (IVZ +1.29%), executed a non-discretionary disposition of 26,002 shares on July 2, 2026, according to an SEC Form 4 filing.

Transaction summaryMetricValueShares sold26,002Transaction value$702,314Post-transaction shares (directly held)125,818Post-transaction value$3.4 millionTransaction value based on SEC Form 4 weighted average sale price ($27.01); post-transaction value based on July 02, 2026 market close ($27.01).

Key questionsWhat was the specific nature of this disposition?
The transaction was executed for the sole purpose of covering tax withholding liabilities associated with the vesting of restricted stock units. Because these shares were withheld by the company to meet regulatory requirements, the move was non-discretionary and did not involve an open-market sale.What is the scale of the insider's remaining equity exposure?
Following this transaction, Jeffrey H. Kupor maintains a direct ownership stake of 125,818 shares. At the July 6, 2026 market close price of $27.83, this remaining position is valued at approximately $3.5 million, ensuring continued alignment with company performance.How has the stock performed leading up to this vesting event?
As of the July 2, 2026 transaction date, Invesco had delivered a one-year total return of 63%. Company OverviewMetricValueShare Price (as of market close 2026-07-06)$27.83Market Capitalization$12.2 billionRevenue (TTM)$6.6 billionNet Income (TTM)-$243.4 millionCompany SnapshotInvesco offers a comprehensive suite of investment products, including mutual funds, unit trusts, exchange-traded funds, closed-end funds, and retirement plans, generating revenue through asset management fees and advisory services.The company operates a diversified asset management business model that generates recurring revenue through management fees charged on assets under management across multiple product categories and geographic markets.Invesco serves institutional investors, financial advisors, and retail investors globally, with a focus on providing scalable investment solutions across equities, fixed income, alternatives, and multi-asset strategies.Invesco Ltd. is a global asset management firm operating from its Atlanta headquarters. The company has established a diversified financial services platform spanning multiple asset classes and distribution channels, positioning itself as a significant player in the competitive asset management industry. With TTM revenue of $6.6 billion, Invesco leverages scale and product breadth to compete across institutional and retail segments.

What this transaction means for investorsThis sale ultimately isn't the kind that should register on anyone's radar, because Kupor didn't actually choose to sell anything. These shares were withheld by Invesco to cover the taxes owed when his restricted stock vested, a bookkeeping step that happens automatically the moment the units convert.

With the noise cleared, what's left is a business seemingly hitting its stride. Invesco recently posted its 11th straight quarter of positive organic growth, pulling in nearly $22 billion of net inflows and ending the quarter at $2.2 trillion in assets. Adjusted earnings rose to $0.57 per share from $0.44 one year earlier, and the board raised the dividend and authorized another $1 billion buyback. CEO Andrew Schlossberg pointed to broad demand across the platform. For long-term investors, the takeaway is to ignore this filing, and instead watch flows and fee rates, especially whether QQQ outflows reverse, since that's what actually moves Invesco.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- Invesco Ltd. (NYSE: IVZ)1, a leading global asset management firm announced today preliminary month-end assets under management (AUM) of $2,470.3 billion, an increase of 0.7% versus previous month-end. The firm delivered net long-term inflows of $8.0 billion in the month. Money market net inflows were $14.3 billion. AUM was positively impacted by favorable market returns which increased AUM by $9 billion. FX movements in the month reduced AUM by $6.4 billion which was partially offset by reinvested distributions of $1.6 billion. Preliminary average total AUM for the quarter through June 30 was $2,368.8 billion, and preliminary average active AUM for the quarter through June 30 was $1,184.3 billion.

Total Assets Under Management

(in billions)

Total

ETFs & Index
Strategies

QQQ

Fundamental
Fixed Income

Fundamental
Equities

Private
Markets

China JV

Multi-
Asset/Other

Global
Liquidity

June 30, 20261

$2,470.3

$753.5

$490.1

$315.5

$318.1

$135.5

$163.2

$79.9

$214.5

May 31, 2026

$2,453.9

$745.8

$494.0

$316.5

$319.5

$135.5

$158.7

$79.6

$204.3

April 30, 2026

$2,339.4

$701.4

$440.3

$315.8

$312.2

$134.1

$154.3

$77.7

$203.6

March 31, 2026

$2,159.5

$638.3

$372.5

$312.5

$287.7

$131.3

$141.9

$74.1

$201.2

1 All June numbers preliminary – subject to adjustment.

About Invesco Ltd.
Invesco Ltd. is one of the world's leading asset management firms serving clients in more than 120 countries. With US$2.2 trillion in assets under management as of Mar. 31, 2026, we deliver a comprehensive range of investment capabilities across public, private, active, and passive. Our collaborative mindset, breadth of solutions and global scale mean we're well positioned to help retail and institutional investors rethink challenges and find new possibilities for success. For more information, visit www.invesco.com.

Category: AUM

Investor Relations Contacts:

Greg Ketron

404-724-4299

Jennifer Church

404-439-3428

Media Relations Contact:

Andrea Raphael

212-323-4202

SOURCE Invesco Ltd.

Also from this source

(Kitco News) – While Q2 was the worst quarter for gold in 12 years, with spiking energy prices raising inflation expectations and introducing the possibility of rate hikes, central bank demand will help gold finish the year on a positive note, according to the new quarterly gold outlook from Invesco.

“The gold price fell by 14.1% in Q2, more than erasing its gains from Q1 and leaving it over $1,500 an ounce off the all-time intraday high set in late-January this year,” wrote Sam Whitehead, Head of Alternative and ESG ETF Product Strategy, Benjamin Jones, Global Head of Research, and David Scales, Senior ETF Investment Editor. “Volatility picked up in April, but most of the decline in the gold price occurred over the following two months. On 24 June, the yellow metal dipped just below $4,000 an ounce for the first time since November 2025. Gold spent the following days bouncing around that psychologically relevant level and ended the quarter at $4,008.”

The authors said this constituted the worst quarter for gold since Q2 2013, when the price fell by 22.7%, but pointed out that these kinds of pullbacks “are not uncommon when any market has risen so strongly for a sustained period, and this latest price correction might prove healthy given gold is still up by 21.3% over the past 12 months.”

They warned, however, that downside risks to the gold price remain. “The next few months could be pivotal for gold, as we watch to see how the Fed reacts to inflation – and whether inflation is sticky or comes down with lower oil prices – and if the US Dollar firms further versus other major currencies,” they said. “Higher interest rates and a stronger USD are generally negative for gold, as the former increases the opportunity cost of holding a non-yielding asset and the latter makes gold more expensive for international (non-US) investors.”

The authors wrote that several headwinds drove the gold price lower during the quarter. “Inflation emerged as a threat that could potentially linger beyond what was previously being priced in, which means interest rates could stay higher for longer,” they said. “The US Dollar strengthened, though only a little, partly in reply to the revised interest rate outlook and, lastly, some of the geopolitical risk premia was removed from the perceived ‘haven’ asset as the market seemed convinced that negotiations between the US and Iran were progressing towards a satisfactory outcome.”

They noted that the conflict’s impact on energy prices resulted in a market focused on inflation. “The longer the conflict continues, the more lasting the impact on inflation not just on oil prices but knock-on effects more broadly,” they said. “WTI Crude ended the quarter at $70/barrel, an indication the market expects supply to resume.”

The authors said easing inflation expectations indicate that the broader market believes the recent inflation will be brought under control. “The question is whether the market is being overly optimistic, given recent actual inflation readings and with the US-Iran situation still potentially volatile.”

They pointed out that PCE inflation hit 4.1% in May, the highest level since April 2023, driven mainly by elevated energy prices, but core PCE, which excludes food and energy, also reached 3.4%, the highest reading since October 2023. “The FOMC, under new Fed Chair Kevin Warsh, had sounded a warning to the market in the minutes following the committee’s April meeting, saying it would “deliver price stability” after inflation has remained above the target 2% rate for five years running.”

The Invesco analysts said the recent gold price correction could be seen as a reasonable response “to the rise in inflation expectations, the Fed’s more hawkish view on interest rates and the recent strength in the US Dollar.”

“The USD eased at the beginning of the quarter but spent most of the period gaining against its major trading partners,” they said. “A stronger USD makes gold more expensive for international (non-US) investors and consumers, which tends to reduce demand from those important segments.”

The authors noted that after a general expectation of further rate cuts, interest rates are now forecast to rise in 2026.

“Earlier this year, the futures market had been predicting Fed rate cuts in 2026, with the only question being how many,” they said. “The CME FedWatch tool was showing practically no chance of a rate hike this year. The inflation pressures mentioned above then shifted the market’s expectations, with the Fed under new Chair Warsh seemingly more committed to addressing the persistence of above-target inflation, with hikes firmly on the table.”

By the end of May the market was pricing in virtually no chance of a cut in 2026, and began entertaining the possibility of rate hikes. 

“When the quarter ended, the market was placing a 33.7% probability of a 25 basis-point increase at the end of July and at least one rate hike (67% chance) by the time the FOMC concludes its September meeting,” they wrote. “The CME FedWatch shows an 83% probability that interest rates will be higher than they are now by the end of the year. Higher interest rates are negative for gold, as it increases the opportunity cost of holding the non-yielding gold asset.”

But despite the rise in inflation expectations, the potential for rate hikes, and the yellow metal’s recent weakness, Invesco maintains a constructive outlook for gold in the second half of 2026.

“[W]e believe much of the structural support for gold remains largely intact,” the authors said. “Central banks look set to continue buying gold to diversify their reserves. The World Gold Council (WGC) reported that a record 45% of central bankers responding to its latest survey said they expected to increase their gold reserves in the next 12 months, while 89% expect gold central bank reserves to increase globally over the coming year.”

They noted that this structural support was reflected in their recent Global Sovereign Asset Management Study, “in which a majority of central banks reported increasing gold allocations over the past three years, with concern over global volatility, inflation protection, and geopolitical uncertainty now among the leading drivers of ongoing gold purchases.”

But while central bank demand is largely price-insensitive, they said, investment demand is sensitive to price momentum. “Rising prices may attract flows into an asset, but falling prices can sometimes encourage selling, particularly when an investor can lock in a profit and needs to access liquidity to reallocate elsewhere,” the authors wrote. “Retail purchases of coins and small gold bars were a strong source of demand throughout the long-term gold rally, and it will be important to see how they respond to the correction.”

“For retail and professional investors, the case for including gold in a portfolio is not based on a single consideration, such as using it only to hedge geopolitical risk, although historically gold has performed this role relatively well,” the Invesco analysts concluded. “Rather, gold can be a useful diversifier as it tends to have low correlation to most assets, especially equities. Gold is a unique asset as it has no issuer, no credit risk, and a long history as a store of value when confidence in currencies, institutions, or market plumbing is questioned.”

Disclaimer: The views expressed in this article are those of the author and may not reflect those of Kitco Metals Inc. The author has made every effort to ensure accuracy of information provided; however, neither Kitco Metals Inc. nor the author can guarantee such accuracy. This article is strictly for informational purposes only. It is not a solicitation to make any exchange in commodities, securities or other financial instruments. Kitco Metals Inc. and the author of this article do not accept culpability for losses and/ or damages arising from the use of this publication.

Invesco Nasdaq Biotechnology ETF offers a lower expense ratio and a higher trailing dividend yield than State Street SPDR S&P Pharmaceuticals ETF. State Street SPDR S&P Pharmaceuticals ETF has delivered a higher 1-year total return and experienced a less severe maximum drawdown than Invesco Nasdaq Biotechnology ETF.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.

It also includes access to the Zacks Style Scores.

What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.

Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.

Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.

How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.

It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Invesco (IVZ - Free Report) Headquartered in Atlanta, GA, Invesco Ltd. operates as an independent investment manager and offers a wide range of investment products and services. The company was incorporated in 1935. As of March 31, 2026, Invesco served clients in more than 120 countries and had AUM worth $2.16 trillion.

IVZ is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.

It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 10.73; value investors should take notice.

Three analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.02 to $2.59 per share. IVZ also boasts an average earnings surprise of +7.9%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, IVZ should be on investors' short list.

The State Street Health Care Select Sector SPDR ETF (XLV +2.63%) provides broad, low-cost exposure to the entire healthcare sector, whereas the Invesco Pharmaceuticals ETF (PJP +2.84%) offers a concentrated bet on 29 specific pharmaceutical companies.

Investors seeking healthcare exposure often weigh broad-market efficiency against niche industry concentration. While both funds operate within the healthcare space, they differ significantly in their scope. The SPDR fund tracks a diversified index of large-cap healthcare stocks, while the Invesco fund homes in on the drug manufacturing and research segment.

Snapshot (cost & size)MetricPJPXLVIssuerInvescoSPDRShare price (as of June 30, 2026)$118.45$158.66Expense ratio0.57%0.08%1-yr return (as of June 30, 2026)49.9%19.8%Dividend yield0.9%1.6%Beta0.450.56AUM$353.9 million$40.9 billionBeta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.

Cost is a major differentiator here; the State Street fund is significantly more affordable with an expense ratio of 0.08%. Additionally, it offers a higher payout for income seekers, with a yield gap of 0.70 percentage points over the Invesco ETF.

Performance & risk comparisonMetricPJPXLVMax drawdown (5 yr)(17.5%)(17.1%)Growth of $1,000 over 5 years (total return)$1,530$1,354What's insideThe SPDR ETF provides exposure across healthcare fields including biotechnology, life sciences, and health technology. Its largest positions include Eli Lilly (LLY +1.35%) at 16.72%, Johnson & Johnson (JNJ +3.35%) at 10.70%, and AbbVie (ABBV +3.90%) at 7.72%. The fund, which holds 59 securities, was launched in 1998. The SPDR ETF has paid $2.53 per share over the trailing 12 months, which on its recent ~$158.66 share price works out to a 1.6% yield.

Invesco’s ETF focuses specifically on 29 U.S. pharmaceutical companies involved in research, development, and distribution. Eli Lilly (5.22%), Abbott Laboratories (ABT +3.49%) (5.16%), and AbbVie (5.14%) are among its largest positions. The fund was launched in 2005. Invesco’s ETF has paid $1.06 per share over the trailing 12 months, which on its recent ~$118.45 share price works out to a 0.9% yield.

For more guidance on ETF investing, check out the full guide at this link.

What this means for investorsPerhaps the greatest difference between these two ETFs is that XLV is literally orders of magnitude larger than PJP in terms of assets under management. That size difference often has knock-on effects. For one, XLV has much higher average trading volume. Additionally, lower average volume for PJP means an increased likelihood of wider bid-ask spreads.

Overall, this seems like a situation where you're paying for your returns (although, as always, it's worth a reminder that past performance is no indication of future results). PJP has a higher expense ratio, but also higher one- and five-year returns. The choice is between PJP's better returns and higher expense ratio, or XLV's massively larger fund with greater liquidity and a bigger dividend yield. The former is probably more appealing to growth investors, while conservative types will likely prefer XLV.

Erin Kennedy has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie, Abbott Laboratories, and Eli Lilly. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.

Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.

The Style Scores are broken down into four categories:

Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.

How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.

That's where the Style Scores come in.

To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.

Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.

A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Invesco (IVZ - Free Report) Headquartered in Atlanta, GA, Invesco Ltd. operates as an independent investment manager and offers a wide range of investment products and services. The company was incorporated in 1935. As of March 31, 2026, Invesco served clients in more than 120 countries and had AUM worth $2.16 trillion.

IVZ is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.

Additionally, the company could be a top pick for growth investors. IVZ has a Growth Style Score of B, forecasting year-over-year earnings growth of 27.6% for the current fiscal year.

Three analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.02 to $2.59 per share. IVZ also boasts an average earnings surprise of +7.9%.

With a solid Zacks Rank and top-tier Growth and VGM Style Scores, IVZ should be on investors' short list.

The aerospace and defense sector often serves as a unique industrial niche, blending long-term government contracts with high-stakes engineering. Investors may look to this space for defense-budget stability or the growth potential of commercial air travel and space exploration. The Invesco Aerospace & Defense ETF (PPA +2.00%) provides a larger, more established vehicle with a lower expense ratio than the First Trust Indxx Aerospace & Defense ETF (MISL +2.07%).

While both ETFs offer concentrated exposure to the defense industry, the Invesco fund's massive assets under management (AUM) and nearly two-decade history provide liquidity and institutional presence that the newer First Trust offering has yet to match.

Snapshot (cost & size)MetricMISLPPAIssuerFirst TrustInvescoShare price$45.77 (as of 2026-06-30)$176.65 (as of 2026-06-30)Expense ratio0.60%0.58%1-yr return (as of 2026-06-30)22.90%25.20%Dividend yield0.30%0.40%Beta0.670.73AUM$790.0 million$8.6 billionBeta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.

The Invesco fund is slightly more affordable, featuring a 0.58% expense ratio compared to 0.60% for the First Trust fund. This 0.02 percentage point yield advantage also provides a marginally higher payout for income-focused investors.

Performance & risk comparisonMetricMISLPPAMax drawdown (3 yr)(17.90%)(15.20%)Growth of $1,000 over 3 years (total return)$2,001$2,126What's insideThe Invesco Aerospace & Defense ETF tracks the SPADE Defense Index, resulting in a portfolio of 60 holdings. While 94% of the fund is in industrials, it also includes a 6% allocation to information technology stocks and less than 1% to communications services. Its top positions feature Boeing Co (BA +3.46%) at 8.7%, GE Aerospace (GE +0.69%) at 8.3%, and RTX (RTX +3.68%) at 6.9%. Launched in 2005, the fund has a trailing-12-month dividend of $0.66 per share.

First Trust Indxx Aerospace & Defense ETF mirrors the Indxx US Aerospace & Defense Index and currently holds 50 stocks. Its largest positions include Palantir Technologies (PLTR +2.99%), Boeing at 8%, and Rocket Lab Corp (RKLB +0.32%) at 7.9%. Its sector mix leans 82.2% toward industrials and 17.8% toward technology, offering more exposure to high-tech defense solutions and space-based platforms. It was launched in 2022. The First Trust fund has paid $0.14 per share over the trailing 12 months, which, on its recent $45.77 share price, works out to a 0.31% yield.

Which fund is the better buy?Over the past year, PPA, the Invesco Aerospace & Defense ETF, has returned 25.2%, edging out MISL, First Trust Indxx Aerospace & Defense ETF with its 22.9% return. Similarly, over the past three years, the Invesco fund has outperformed First Trust’s offering, 28.8% to 26.1%.  First Trust is hurt by its short track record, since 5- and 10-year time frames for long-term performance are desirable.

First Trust is more heavily weighted in its top 10 stocks, at 62%, than Invesco, with 55%. Generally, if you’re buying an ETF, you want some diversification, so less concentration in the top 10 is preferable. The Invesco fund also offers a bit of foreign exposure (Israel), at just over 4%, whereas the First Trust fund is all U.S. equities.

The performance of both funds has been good, and there is reason to expect aerospace and defense stocks to remain strong. On balance, however, the Invesco  Aerospace & Defense ETF, PPA, gets the nod for performance and portfolio construction.

For more guidance on ETF investing, check out the full guide at this link.

Brendan Coffey has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Boeing, GE Aerospace, Palantir Technologies, RTX, and Rocket Lab. The Motley Fool has a disclosure policy.

Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- Invesco Ltd. (NYSE: IVZ) will release its second quarter 2026 results on Tuesday, July 28, 2026. The earnings release and presentation materials are scheduled to be released and posted to the Investor Relations section of the Company's website, invesco.com/corporate, at approximately 7 a.m. ET. A conference call to discuss Invesco's results will be held at 9 a.m. ET on that day; the live audio webcast and replay can be accessed through the same website under Events and Earnings Releases.

Those wishing to participate should call:

US and Canada toll free:

866-803-2143

International:

1-210-795-1098

Passcode: Invesco

The presentation will be made available via a simultaneous webcast at invesco.com/corporate.

An audio replay will be available approximately one hour after the call:

US and Canada toll free:

866-360-7726

International:

1-203-369-0178

The replay will be removed after Aug. 12, 2026.

About Invesco Ltd.
Invesco Ltd. is one of the world's leading asset management firms serving clients in more than 120 countries. With US$2.2 trillion in assets under management as of March 31, 2026, we deliver a comprehensive range of investment capabilities across public, private, active, and passive. Our collaborative mindset, breadth of solutions and global scale mean we're well positioned to help retail and institutional investors rethink challenges and find new possibilities for success. For more information, visit www.invesco.com.

Investor Relations Contacts:

Greg Ketron

404-724-4299

Jennifer Church

404-439-3428

Media Relations Contact:

Andrea Raphael

212-323-4202

SOURCE Invesco Ltd.

Also from this source

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.

It also includes access to the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.

Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +24% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Invesco (IVZ - Free Report) Headquartered in Atlanta, GA, Invesco Ltd. operates as an independent investment manager and offers a wide range of investment products and services. The company was incorporated in 1935. As of March 31, 2026, Invesco served clients in more than 120 countries and had AUM worth $2.16 trillion.

IVZ is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.

Momentum investors should take note of this Finance stock. IVZ has a Momentum Style Score of B, and shares are up 4% over the past four weeks.

Four analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.05 to $2.57 per share. IVZ also boasts an average earnings surprise of +7.9%.

With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, IVZ should be on investors' short list.

Invesco S&P 500 Equal Weight Consumer Staples ETF (RSPS 0.28%) provides diversified exposure to defensive stocks, while iShares U.S. Consumer Staples ETF (IYK +0.29%) offers a more concentrated, market-cap-weighted portfolio with historically stronger total returns.

Both funds focus on the consumer staples sector, which investors often seek out as a defensive harbor during market volatility. While RSPS treats every constituent equally to avoid overexposure to giant companies, IYK follows a traditional market-cap approach that leans heavily on industry leaders.

Snapshot (cost & size)MetricRSPSIYKIssuerInvescoiSharesExpense ratio0.40%0.38%1-yr return (as of June 18, 2026)0.1%2.9%Dividend yield2.8%2.7%Beta0.590.50AUM$225.5 million$1.3 billionBeta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.

Both funds are cost-efficient, though the iShares fund is slightly more affordable. While RSPS offers a slightly higher dividend yield of 2.8%, IYK provides a similar payout at 2.7%.

Performance & risk comparisonMetricRSPSIYKMax drawdown (5 yr)(18.60%)(15.00%)Growth of $1,000 over 5 years (total return)$1,071$1,381What's insideThe iShares ETF targets U.S. companies in the consumer defensive sector using a market-capitalization-weighting strategy. With 54 holdings, its largest positions include Procter & Gamble (PG 0.40%) at 13.45%, Coca-Cola(KO +0.08%) at 12.38%, and Philip Morris International (PM +0.07%) at 11.14%. The portfolio is primarily composed of consumer defensive stocks at 85%, with additional exposure to healthcare at 11% and basic materials at 3%. Launched in 2000, it has a trailing-12-month dividend payout of $1.89 per share.

In contrast, the Invesco ETF tracks the S&P 500 Equal Weight Consumer Staples Index, which assigns an equal weight to every staples company in the S&P 500. This 37-holding portfolio includes Monster Beverage (MNST +0.68%) at 3.32%, Casey's General Stores (CASY 0.58%) at 3.30%, and Keurig Dr Pepper (KDP 0.05%) at 3.18%. It is heavily concentrated in consumer defensive stocks. Launched in 2006, it has a trailing-12-month dividend payout of $0.84 per share.

For more guidance on ETF investing, check out the full guide at this link.

What this means for investorsWhile I think both of these ETFs would likely appeal to defensive investors, the fundamental difference in their approach to position sizing is probably the deciding factor in choosing one over the other.

RSPS may be more attractive to conservative investors given its equal-weight strategy; the smaller position sizing reduces concentration risk. Due to IYK's market-cap-weighting approach, the ETF is inherently far more reliant on just a few stocks to fuel its performance. The fund's top three holdings -- P&G, Coca-Cola, and Philip Morris -- account for roughly 37% of the portfolio. And while these are generally stalwart stocks, investors might want to note that P&G has underperformed the market by a wide margin over the past five years, up only 14% versus the S&P 500's 80% gain. Despite that, the iShares ETF has delivered better returns recently.

One final thing to consider is their relative size. RSPS has significantly fewer assets under management, as well as much lower average trading volume. If liquidity is an important consideration, IYK may be the better option for your portfolio.

Erin Kennedy has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Monster Beverage. The Motley Fool recommends Casey's General Stores and Philip Morris International. The Motley Fool has a disclosure policy.

Invesco KBW Bank ETF (KBWB +1.11%) offers broader exposure to major U.S. money center banks and national institutions, while iShares U.S. Regional Banks ETF (IAT +0.57%) provides a more concentrated bet on the domestic regional banking sector.

These ETFs allow investors to target the financial sector with differing levels of specificity. While both concentrate on bank equities, their underlying indexes select and weigh holdings differently, leading to variations in liquidity, price volatility, and total returns. With assets under management (AUM) exceeding $6 billion, KBWB offers deeper liquidity than the smaller IAT.

Snapshot (cost & size)MetricIATKBWBIssueriSharesInvescoExpense ratio0.38%0.35%1-yr return (as of June 19, 2026)27.8%37.8%Dividend yield2.8%2.1%Beta1.281.26AUM$624.3 million$6.3 billionBeta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.

The Invesco fund is marginally more affordable than the iShares ETF, but that 3-basis-point difference is unlikely to sway an investor one way or another. However, IAT may appeal to income-oriented investors due to its higher trailing-12-month dividend yield of 2.8%.

Performance & risk comparisonMetricIATKBWBMax drawdown (5 yr)(55.5%)(49.3%)Growth of $1,000 over 5 years (total return)$1,264$1,744What's insideThe Invesco ETF tracks the KBW Nasdaq Bank Index, which focuses on national money centers and regional establishments. Its portfolio of 26 holdings leans into diversified financial giants. Its largest positions include Morgan Stanley (MS +1.55%) at 9.49%, Goldman Sachs (GS +0.52%) at 8.99%, and Bank of America (BAC +2.10%) at 7.97%. Launched in 2011, it has a trailing-12-month dividend payout of $1.80 per share.

Conversely, the iShares fund offers more targeted exposure, strictly following U.S.-based stocks within the regional banking industry. It holds 31 companies, all within the financial services sector. Its largest positions include PNC Financial (PNC +0.84%) at 14.67%, U.S. Bancorp (USB +0.86%) at 14.17%, and Truist Financial (TFC +1.30%) at 9.6%. Launched in 2006, IAT has a trailing-12-month dividend payout of $1.62 per share.

For more guidance on ETF investing, check out the full guide at this link.

What this means for investorsAt a glance, Invesco's ETF may be more appealing to most investors. KBWB has posted higher returns recently and a lower five-year max drawdown. It pays a smaller dividend, but investors know a dividend yield moves inversely to a stock's price; when a stock goes up, the dividend will fall, all else equal. The Invesco ETF's one- and five-year returns could more than account for its slightly lower dividend yield. Finally, the fund is roughly 10 times the size of IAT, with much higher average trading volume and accordingly increased liquidity.

One final consideration is concentration risk. KBWB's top three holdings make up about 26% of the fund. Meanwhile, IAT's three largest positions account for about 38% of the portfolio. Some investors may not feel comfortable with that level of concentration in the iShares ETF, myself among them.

Bank of America is an advertising partner of Motley Fool Money. Erin Kennedy has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Goldman Sachs Group, Truist Financial, and U.S. Bancorp. The Motley Fool has a disclosure policy.

5.72K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Invesco Ltd. (IVZ) Shareholder/Analyst Call Prepared Remarks Transcript

A month has gone by since the last earnings report for Invesco (IVZ - Free Report) . Shares have added about 7.7% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is Invesco due for a pullback? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent drivers for Invesco Ltd. before we dive into how investors and analysts have reacted as of late.

Invesco’s Q1 Earnings Miss Despite Higher AUM & RevenuesInvesco’s first-quarter 2026 adjusted earnings of 57 cents per share lagged the Zacks Consensus Estimate by a penny. The bottom line increased 29.5% from the prior-year quarter.

The results primarily benefited from an increase in adjusted revenues and growth in AUM balance. However, an increase in adjusted expenses was a headwind.

Net income attributable to common shareholders (GAAP basis) was $230.4 million or 51 cents per share, up from $171.1 million or 38 cents per share in the year-ago quarter.

Adjusted Revenues Improve, Adjusted Expenses RiseAdjusted net revenues in the quarter were $1.26 billion, up 14% year over year. The top line marginally missed the Zacks Consensus Estimate of $1.27 billion. The rise in revenues was driven by higher average AUM, favorable foreign exchange rate changes and revenues earned from Invesco QQQ Trust following its conversion.

Adjusted operating expenses were $828.3 million, up 9.1% year over year.

The adjusted operating margin was 34.5%, up from 31.5% a year ago.

AUM Balance IncreasesAs of March 31, 2026, AUM was a record $2.16 trillion, up 17.1% year over year. The average AUM at the end of the first quarter totaled $2.22 trillion, up 18%.

Client demand remained supportive across IVZ’s multiple investment capabilities. Net long-term inflows were led by ETFs and Index products ($18.6 billion) and the China joint venture ($8.7 billion), with additional contributions from Fundamental Fixed Income ($3.7 billion) and Multi-Asset/Other strategies ($3.6 billion). Private Markets also generated positive net inflows of $0.4 billion.

Those positives were partially offset by outflows tied to factor and product rotations. QQQ recorded net long-term outflows of $10.8 billion in the quarter, while Fundamental Equities saw net outflows of $2.4 billion.

By geography, Asia Pacific and EMEA produced net long-term inflows of $13.2 billion and $7.6 billion, respectively, while the Americas added $1.0 billion.

Decent Balance SheetAs of March 31, 2026, cash and cash equivalents were $806.9 million compared with $1.04 billion as of Dec. 31, 2025.

The long-term debt was $1.97 billion. The redemption of $500 million of senior notes that matured in mid-January 2026 raised the credit facility balance to $1.1 billion.

Capital Distribution UpdatesIn the reported quarter, Invesco repurchased 1.6 million shares for $40 million.

In February, the board authorized an additional $1.0 billion common share repurchase plan with no expiration date. This reinforces management’s emphasis on ongoing capital return alongside balance sheet management.

OutlookManagement expects one-time implementation costs of the Alpha investment platform to be $10-$15 million per quarter, trending toward higher end as implementation progresses, with completion targeted by the end of 2026. Further, as more AUM transitions onto the platform during 2026, the incremental expense associated with AUM on the system is expected to build through the year, reaching approximately $10 million per quarter later in the year. Hence, the combined costs related to the hybrid platform are expected to be $20 million to $25 million higher in 2026 than in 2025.

Beginning in the third quarter of 2026, operating income is expected to be negatively impacted initially by the Canada fund deal, including an operating expense reduction of $5 million to $10 million per quarter (i.e., a cost benefit that partially offsets other headwinds). Over time, the operating expense benefit is expected to move closer to about $10 million per quarter.

Further, for 2026, the company expects $3.275 billion in operating expenses.

Non-GAAP effective tax rate is expected to be in the range of 25-26% for the second quarter of 2026.

How Have Estimates Been Moving Since Then?Since the earnings release, investors have witnessed a downward trend in estimates review.

VGM ScoresAt this time, Invesco has a nice Growth Score of B, a score with the same score on the momentum front. Following the exact same course, the stock has a score of B on the value side, putting it in the top 40% for value investors.

Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Invesco has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry PlayerInvesco belongs to the Zacks Financial - Investment Management industry. Another stock from the same industry, Cohen & Steers Inc (CNS - Free Report) , has gained 4.7% over the past month. More than a month has passed since the company reported results for the quarter ended March 2026.

Cohen & Steers reported revenues of $145.64 million in the last reported quarter, representing a year-over-year change of +8.3%. EPS of $0.79 for the same period compares with $0.75 a year ago.

For the current quarter, Cohen & Steers is expected to post break-even earnings per share, indicating a change of 0% from the year-ago quarter. The Zacks Consensus Estimate has changed 0% over the last 30 days.

Cohen & Steers has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of F.

, /PRNewswire/ -- CI Global Asset Management ("CI GAM") and Invesco Ltd. (NYSE: IVZ) today announced the successful completion of CI GAM's acquisition of the management agreements relating to Invesco's Canadian fund business with combined total assets under management of approximately C$27 billion.

CI GAM English Effective today, CI GAM, the Canadian asset management subsidiary of CI Financial Corp. ("CI"), has become manager of 98 mutual funds and exchange-traded funds previously offered by Invesco Canada Ltd. The transaction, which was first announced on January 13, 2026, has increased CI GAM's assets under management to approximately C$175 billion.

Invesco and CI GAM have also formed a long-term strategic partnership under which Invesco affiliates continue to provide portfolio management services to 61 of the funds through a sub-advisory arrangement with total assets under management of approximately C$13 billion, ensuring a consistent investment experience for securityholders in those funds.

"This transaction strengthens our position as a leader in the Canadian investment fund industry, significantly adding to our assets under management and broadening our capabilities," said Kurt MacAlpine, CI Chief Executive Officer. "We have enhanced our fund lineup with an extensive range of new strategies, including a robust ETF franchise – creating one of the industry's most comprehensive and diverse product offerings.

"This acquisition demonstrates our deep commitment to investing in the development and growth of all aspects of our Canadian wealth and asset management operations. As CI GAM continues to scale, we are equipped with greater resources to deliver investment excellence and effective, high-quality services and solutions that meet the needs of Canadian advisors and investors."

"Invesco remains committed to serving Canadian investors with our wide range of global investment strategies, and we look forward to continued growth through our partnership with CI GAM, one of Canada's leading wealth and investment managers," said Andrew Schlossberg, Chief Executive Officer of Invesco Ltd. "We also look forward to potentially jointly developing investment solutions for the Canadian wealth market in the future through our ongoing strategic relationship with CI GAM."

Prior to the completion of the transaction, securityholders of each applicable Invesco Canada investment fund approved the change of manager for their respective fund at meetings held in April 2026.

Given the change in portfolio management, CI GAM will rebrand 37 funds under the CI banner, effective on or about July 31, 2026. Further details will be disclosed in a separate press release to be issued later this week.

Contact information for Client Relations for the Invesco funds has not changed. Investors can continue to reach that team by phone at 1-800-874-6275 (English) or 1-800-200-5376 (French) or by email at [email protected] (English) or [email protected] (French), Monday to Friday, 9 a.m. to 5 p.m. ET.

Morgan Stanley & Co. LLC acted as financial advisor and Borden Ladner Gervais LLP served as legal advisor to Invesco. Jefferies Securities Inc. acted as financial advisor and Stikeman Elliott LLP served as legal advisor to CI GAM.

About Invesco Ltd.

Invesco Ltd. is one of the world's leading asset management firms serving clients in more than 120 countries. With US$2.2 trillion in assets under management as of March 31, 2026, we deliver a comprehensive range of investment capabilities across public, private, active, and passive. Our collaborative mindset, breadth of solutions and global scale mean we're well positioned to help retail and institutional investors rethink challenges and find new possibilities for success. For more information, visit www.invesco.com.

About CI Global Asset Management

CI Global Asset Management ("CI GAM") is one of Canada's leading investment management firms, providing a comprehensive suite of solutions – including mutual funds, exchange-traded funds and alternative investments – to help Canadians achieve their financial goals. Founded in 1965, CI GAM has built an enduring legacy of innovation, disciplined portfolio management and commitment to investor success. Our investment team brings deep expertise in fundamental research, portfolio construction and risk management to deliver results across a broad range of asset classes. We partner with financial advisors, wealth management firms and institutions to serve more than 1.3 million investors. CI GAM is a subsidiary of Toronto-based CI Financial Corp., a diversified global asset and wealth management company. For more information, visit www.ci.com or follow us on LinkedIn.

Forward-Looking Information and Statements

This press release contains "forward-looking information" and "forward looking statements" (collectively, "FLS") within the meaning of applicable securities laws. FLS may relate to future outlook and anticipated events or results and may include information regarding business strategy, growth strategy, operations, results, plans and objectives. Particularly, information regarding our expectations of future results, performance, achievements, prospects or opportunities is FLS. In some cases, FLS can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "scheduled", "estimates", "outlook", "forecasts", "projection", "prospects", "strategy", "intends", "anticipates", "does not anticipate", "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", "will", "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain FLS. Statements containing FLS are not historical facts but instead represent management's expectations, estimates and projections regarding future events or circumstances. 

Undue reliance should not be placed on FLS. The FLS in this press release is based on opinions, estimates and assumptions in light of experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we currently believe are appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the FLS, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. Further, FLS is subject to known and unknown risks, uncertainties and other factors that may cause actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such FLS, including but not limited to, those described in this press release. 

There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward looking information, which speaks only as of the date made. The FLS contained in this press release represents our expectations as of the date of this press release and is subject to change after such date. Each of CI and Invesco disclaim any intention or obligation or undertaking to update or revise any FLS whether as a result of new information, future events or otherwise, except as required by applicable law.

CI Global Asset Management is a registered business name of CI Investments Inc. 

©CI Investments Inc. 2026. All rights reserved. 

Contacts:

Invesco
Invesco Investor Relations: Greg Ketron +1-404-724-4299; Jennifer Church +1-404-439-3428
Invesco Media Relations: Andrea Raphael +1-929-729-3843; [email protected]

CI Global Asset Management
Murray Oxby
Vice-President, Corporate Communications
416-681-3254
[email protected]

SOURCE Invesco Ltd.